Immunosuppressive Treatment for Idiopathic Nephrotic Syndrome with Corticosteroids and Cyclophosphamide: Factors Associated with a Favourable Outcome

Overview

Journal Clin Drug Investig

Date 2008 Mar 29

PMID 18370542

Citations 1

Authors

M Pirisi

R Faedda

A Satta

E Bartoli

Affiliations

Soon will be listed here.

Abstract

Objective: We report the results of a combined immunosuppressive schedule for the treatment of patients with idiopathic nephrotic syndrome, in which prednisone and cyclophosphamide were given in four phases: induction, maintenance, tapering and discontinuation.

Patients And Outcome Measures: Sixty-seven patients with nephrotic syndrome, followed for an average of 7.1 +/- 4.5 years, were studied. Treatment outcomes were remission, progression, end-stage renal disease and death.

Results: At the end of the follow-up, 72% of patients maintained a complete remission. Stepwise logistic regression showed that the cumulative dose of cyclophosphamide was the only independent predictor of a favourable outcome, being associated both with complete remission of the nephrotic syndrome and with lack of progression to chronic renal failure.

Conclusion: We suggest that the combination treatment may be indicated in all histological subgroups of nephrotic syndrome, provided that prednisone is given at high doses on alternate days, cyclophosphamide is given for 6 months, and relapses are treated with the same schedule. The adverse effects of treatment, however, require the adoption of a programme to prevent bone loss, infertility, bladder cancer and infections.

Citing Articles

Interventions for minimal change disease in adults with nephrotic syndrome.

Palmer S, Nand K, Strippoli G Cochrane Database Syst Rev. 2008; (1):CD001537.

PMID: 18253993 PMC: 7025787. DOI: 10.1002/14651858.CD001537.pub4.

References

Earley L, HAVEL R, HOPPER Jr J, Grausz H . Nephrotic syndrome. Calif Med. 1971; 115(5):23-41. PMC: 1518182. View

Alexopoulos E, Sakellariou G, Memmos D, Karamitsos K, Leontsini M, Papadimitriou M . Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy. Am J Kidney Dis. 1993; 21(5):497-503. DOI: 10.1016/s0272-6386(12)80395-7. View

Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E . Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994; 67(1):59-65. DOI: 10.1159/000187889. View

Churg J, Habib R, White R . Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. 1970; 760(1):1299-302. DOI: 10.1016/s0140-6736(70)91905-7. View

Abbate M, Remuzzi G . Innovative strategies for pharmacological intervention in immune damage to the kidney. Nephrol Dial Transplant. 1995; 10(7):1131-6. View

Levine E, Bloomfield C . Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992; 19(1):47-84. View

Pedersen-Bjergaard J, Specht L, Larsen S, Ersboll J, Struck J, Hansen M . Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987; 2(8550):83-8. DOI: 10.1016/s0140-6736(87)92744-9. View

Lewis E . Chlorambucil for childhood nephrosis: a word of caution. N Engl J Med. 1980; 302(17):963-4. DOI: 10.1056/NEJM198004243021709. View

Pedersen-Bjergaard J, Ersboll J, Sorensen H, Keiding N, Larsen S, Philip P . Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985; 103(2):195-200. DOI: 10.7326/0003-4819-103-2-195. View

10.

Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K . Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis. 1991; 17(6):687-92. DOI: 10.1016/s0272-6386(12)80353-2. View

11.

. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int. 1981; 20(6):765-71. DOI: 10.1038/ki.1981.209. View

12.

Boumpas D, Austin 3rd H, Vaughan E, Yarboro C, Klippel J, Balow J . Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993; 119(5):366-9. DOI: 10.7326/0003-4819-119-5-199309010-00003. View

13.

Faedda R, Pirisi M, Satta A, Tanda F, Bartoli E . Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions. Clin Nephrol. 1996; 46(4):237-44. View

14.

Honkanen E, Willebrand E, Teppo A, Tornroth T, Gronhagen-Riska C . Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. Kidney Int. 1998; 53(4):909-17. DOI: 10.1111/j.1523-1755.1998.00833.x. View

15.

Faedda R, Pirisi M, Satta A, Bosincu L, Bartoli E . Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment. Clin Pharmacol Ther. 1996; 60(5):576-81. DOI: 10.1016/S0009-9236(96)90154-X. View

16.

Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N . Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993; 328(24):1747-52. DOI: 10.1056/NEJM199306173282404. View

17.

Lee J, Yamauchi H, HOPPER Jr J . The association of cancer and the nephrotic syndrome. Ann Intern Med. 1966; 64(1):41-51. DOI: 10.7326/0003-4819-64-1-41. View

18.

Orth S, Ritz E . The nephrotic syndrome. N Engl J Med. 1998; 338(17):1202-11. DOI: 10.1056/NEJM199804233381707. View

19.

Schieppati A, Mosconi L, Perna A, MECCA G, Bertani T, Garattini S . Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993; 329(2):85-9. DOI: 10.1056/NEJM199307083290203. View

20.

Faedda R, Palomba D, Satta A, Pirisi M, Tanda F, Bartoli E . Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Clin Nephrol. 1995; 44(6):367-75. View